Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network

eLife

Volumn 2014, Issue 3, 2014, Pages

  Nwachukwu, Jerome C ^a   Srinivasan, Sathish ^a   Bruno, Nelson E ^a   Parent, Alex A ^b   Hughes, Travis S ^a   Pollock, Julie A ^b   Gjyshi, Olsi ^a   Cavett, Valerie ^a   Nowak, Jason ^a   Garcia Ordonez, Ruben D ^a   Houtman, René ^c   Griffin, Patrick R ^a   Kojetin, Douglas J ^a   Katzenellenbogen, John A ^b   Conkright, Michael D ^a   Nettles, Kendall W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c PamGene International BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(E) 1 (3 FLUORO 4 METHOXYSTYRYL) 3,5 DIMETHOXYBENZENE; (E) 5 (3 FLUORO 4 HYDROXYSTYRYL)BENZENE 1,3 DIOL F RESVERATROL; DIAZEPAM BINDING INHIBITOR; DIETHYL 3,5 DIMETHOXYBENZYLPHOSPHONATE; E1A ASSOCIATED P300 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FORSKOLIN; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PEPTIDES AND PROTEINS; PROSTAGLANDIN E RECEPTOR 4; RESVERATROL; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 1; ROLIPRAM; TNF RECEPTOR SUPERFAMILY MEMBER 11B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENYLATE KINASE; CYCLIC AMP; LIGAND; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLUMN CHROMATOGRAPHY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; PROMOTER REGION; PROTEIN CONFORMATION;

ADENYLATE KINASE; CYCLIC AMP; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIGANDS; MCF-7 CELLS; PROMOTER REGIONS, GENETIC; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STILBENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899621303     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.02057     Document Type: Article

References (100)

1. Aarts, J.M., Wang, S., Houtman, R., van Beuningen, R.M., Westerink, W.M., Van De Waart, B.J., Rietjens, I.M., and Bovee, T.F. (2013). Robust array-based coregulator binding assay predicting ERalpha-agonist potency and generating binding profiles reflecting ligand structure. Chemical research in toxicology 26, 336-346.
2. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221.
3. Ashby, J., Tinwell, H., Pennie, W., Brooks, A.N., Lefevre, P.A., Beresford, N., and Sumpter, J.P. (1999). Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. Journal of applied toxicology: JAT 19, 39-45.
4. Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., and Karin, M. (1995). Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of Ikappa B synthesis. Science 270, 286-290.
5. Baur, J.A., and Sinclair, D.A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nature reviews. Drug discovery 5, 493-506.
6. Ben-Neriah, Y., and Karin, M. (2011). Inflammation meets cancer, with NF-kappaB as the matchmaker. Nature immunology 12, 715-723.
7. Bhat, K.P., Lantvit, D., Christov, K., Mehta, R.G., Moon, R.C., and Pezzuto, J.M. (2001). Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer research 61, 7456-7463.
8. Bock, A., Chirinda, B., Krebs, F., Messerer, R., Batz, J., Muth, M., Dallanoce, C., Klingenthal, D., Trankle, C., Hoffmann, C., et al. (2013). Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. Nat Chem Biol.
9. Bock, A., Chirinda, B., Krebs, F., Messerer, R., Batz, J., Muth, M., Dallanoce, C., Klingenthal, D., Trankle, C., Hoffmann, C., et al. (2014). Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. Nat Chem Biol 10, 18-20.
10. Bookout, A.L., Jeong, Y., Downes, M., Yu, R.T., Evans, R.M., and Mangelsdorf, D.J. (2006). Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789-799.
11. Bookout, A.L., and Mangelsdorf, D.J. (2003). Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nuclear receptor signaling 1, e012.
12. Bowers, J.L., Tyulmenkov, V.V., Jernigan, S.C., and Klinge, C.M. (2000). Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-3667.
13. Bruning, J.B., Parent, A.A., Gil, G., Zhao, M., Nowak, J., Pace, M.C., Smith, C.L., Afonine, P.V., Adams, P.D., Katzenellenbogen, J.A., et al. (2010). Coupling of receptor conformation and ligand orientation determine graded activity. Nat Chem Biol 6, 837-843.
14. Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.A., and Carlquist, M. (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758.
15. Bulynko, Y.A., and O'Malley, B.W. (2010). Nuclear Receptor Coactivators: Structural and Functional Biochemistry. Biochemistry.
16. Carroll, M.J., Gromova, A.V., Miller, K.R., Tang, H., Wang, X.S., Tripathy, A., Singleton, S.F., Collins, E.J., and Lee, A.L. (2011). Direct detection of structurally resolved dynamics in a multiconformation receptor-ligand complex. Journal of the American Chemical Society 133, 6422-6428.
17. Chen, D., Huang, S.M., and Stallcup, M.R. (2000). Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. J Biol Chem 275, 40810-40816.
18. Chen, L.F., and Greene, W.C. (2004). Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 5, 392-401.
19. Chinenov, Y., Sacta, M.A., Cruz, A.R., and Rogatsky, I. (2008). GRIP1-associated SET-domain methyltransferase in glucocorticoid receptor target gene expression. Proc Natl Acad Sci U S A 105, 20185-20190.
20. Choi, J.H., Banks, A.S., Kamenecka, T.M., Busby, S.A., Chalmers, M.J., Kumar, N., Kuruvilla, D.S., Shin, Y., He, Y., Bruning, J.B., et al. (2011). Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477-481.
21. Cicatiello, L., Addeo, R., Sasso, A., Altucci, L., Petrizzi, V.B., Borgo, R., Cancemi, M., Caporali, S., Caristi, S., Scafoglio, C., et al. (2004). Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Molecular and cellular biology 24, 7260-7274.
22. Csiszar, A., Labinskyy, N., Podlutsky, A., Kaminski, P.M., Wolin, M.S., Zhang, C., Mukhopadhyay, P., Pacher, P., Hu, F., de Cabo, R., et al. (2008). Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. American journal of physiology. Heart and circulatory physiology 294, H2721-2735.
23. Cvoro, A., Tzagarakis-Foster, C., Tatomer, D., Paruthiyil, S., Fox, M.S., and Leitman, D.C. (2006). Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21, 555-564.
24. DeNardo, D.G., Cuba, V.L., Kim, H., Wu, K., Lee, A.V., and Brown, P.H. (2007). Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol 277, 13-25.
25. Deng, J.Y., Hsieh, P.S., Huang, J.P., Lu, L.S., and Hung, L.M. (2008). Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 57, 1814-1823.
26. Elangovan, S., Ramachandran, S., Venkatesan, N., Ananth, S., Gnana-Prakasam, J.P., Martin, P.M., Browning, D.D., Schoenlein, P.V., Prasad, P.D., Ganapathy, V., et al. (2011). SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor alpha in breast cancer. Cancer research 71, 6654-6664.
27. Faggioli, L., Costanzo, C., Merola, M., Furia, A., and Palmieri, M. (1997). Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF-kappaB. Biochem Biophys Res Commun 233, 507-513.
28. Fernandes, I., Bastien, Y., Wai, T., Nygard, K., Lin, R., Cormier, O., Lee, H.S., Eng, F., Bertos, N.R., Pelletier, N., et al. (2003). Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell 11, 139-150.
29. Fletcher, T.M., Xiao, N., Mautino, G., Baumann, C.T., Wolford, R., Warren, B.S., and Hager, G.L. (2002). ATP-dependent mobilization of the glucocorticoid receptor during chromatin remodeling. Molecular and cellular biology 22, 3255-3263.
30. Garcia-Bassets, I., Kwon, Y.S., Telese, F., Prefontaine, G.G., Hutt, K.R., Cheng, C.S., Ju, B.G., Ohgi, K.A., Wang, J., Escoubet-Lozach, L., et al. (2007). Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 128, 505-518.
31. Ge, H., Zhang, J.F., Guo, B.S., He, Q., Wang, B.Y., He, B., and Wang, C.Q. (2007). Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma. Vascular pharmacology 46, 114-121.
32. Gehm, B.D., McAndrews, J.M., Chien, P.Y., and Jameson, J.L. (1997). Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 94, 14138-14143.
33. Ghisletti, S., Meda, C., Maggi, A., and Vegeto, E. (2005). 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Molecular and cellular biology 25, 2957-2968.
34. Han, W.D., Zhao, Y.L., Meng, Y.G., Zang, L., Wu, Z.Q., Li, Q., Si, Y.L., Huang, K., Ba, J.M., Morinaga, H., et al. (2007). Estrogenically regulated LRP16 interacts with estrogen receptor alpha and enhances the receptor's transcriptional activity. Endocr Relat Cancer 14, 741-753.
35. Heldring, N., Pawson, T., McDonnell, D., Treuter, E., Gustafsson, J.A., and Pike, A.C. (2007). Structural insights into corepressor recognition by antagonist-bound estrogen receptors. J Biol Chem 282, 10449-10455.
36. Hershko, D.D., Robb, B.W., Wray, C.J., Luo, G.J., and Hasselgren, P.O. (2004). Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-kappaB in cultured caco-2 cells. J Cell Biochem 91, 951-961.
37. Huang, S.M., and Cheng, Y.S. (2004). Analysis of two CBP (cAMP-response-element-binding protein-binding protein) interacting sites in GRIP1 (glucocorticoid-receptor-interacting protein), and their importance for the function of GRIP1. Biochem J 382, 111-119.
38. Hughes, T.S., Chalmers, M.J., Novick, S., Kuruvilla, D.S., Chang, M.R., Kamenecka, T.M., Rance, M., Johnson, B.A., Burris, T.P., Griffin, P.R., et al. (2012). Ligand and receptor dynamics contribute to the mechanism of graded PPARgamma agonism. Structure 20, 139-150.
39. Ji Yu, E., Kim, S.H., Heo, K., Ou, C.Y., Stallcup, M.R., and Kim, J.H. (2011). Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor {alpha} activity and co-activator synergy. Nucleic Acids Res 39, 6932-6943.
40. Jung, S.Y., Malovannaya, A., Wei, J., O'Malley, B.W., and Qin, J. (2005). Proteomic analysis of steady-state nuclear hormone receptor coactivator complexes. Mol Endocrinol 19, 2451-2465.
41. Karmakar, S., Foster, E.A., and Smith, C.L. (2009). Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology 150, 1588-1596.
42. Kim, M.Y., Woo, E.M., Chong, Y.T., Homenko, D.R., and Kraus, W.L. (2006). Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 20, 1479-1493.
43. King, E.M., Chivers, J.E., Rider, C.F., Minnich, A., Giembycz, M.A., and Newton, R. (2013). Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation and transrepression-dependent mechanisms. PLoS One 8, e53936.
44. Leo, C., and Chen, J.D. (2000). The SRC family of nuclear receptor coactivators. Gene 245, 1-11.
45. Lu, X., Ma, L., Ruan, L., Kong, Y., Mou, H., Zhang, Z., Wang, Z., Wang, J.M., and Le, Y. (2010). Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. Journal of neuroinflammation 7, 46.
46. Lupien, M., Eeckhoute, J., Meyer, C.A., Krum, S.A., Rhodes, D.R., Liu, X.S., and Brown, M. (2009). Coactivator function defines the active estrogen receptor alpha cistrome. Molecular and cellular biology 29, 3413-3423.
47. Malovannaya, A., Lanz, R.B., Jung, S.Y., Bulynko, Y., Le, N.T., Chan, D.W., Ding, C., Shi, Y., Yucer, N., Krenciute, G., et al. (2011). Analysis of the human endogenous coregulator complexome. Cell 145, 787-799.
48. McInerney, E.M., and Katzenellenbogen, B.S. (1996). Different regions in activation function-1 of the human estrogen receptor required for antiestrogen and estradiol-dependent transcription activation. J Biol Chem 271, 24172-24178.
49. Medzhitov, R., and Horng, T. (2009). Transcriptional control of the inflammatory response. Nat Rev Immunol 9, 692-703.
50. Meijsing, S.H., Pufall, M.A., So, A.Y., Bates, D.L., Chen, L., and Yamamoto, K.R. (2009). DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324, 407-410.
51. Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M., and Gannon, F. (2003). Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115, 751-763.
52. Nettles, K.W., Bruning, J.B., Gil, G., Nowak, J., Sharma, S.K., Hahm, J.B., Kulp, K., Hochberg, R.B., Zhou, H., Katzenellenbogen, J.A., et al. (2008a). NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. Nat Chem Biol 4, 241-247.
53. Nettles, K.W., Gil, G., Nowak, J., Metivier, R., Sharma, V.B., and Greene, G.L. (2008b). CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. Mol Endocrinol 22, 263-272.
54. Nettles, K.W., and Greene, G.L. (2005). Ligand control of coregulator recruitment to nuclear receptors. Annual review of physiology 67, 309-333.
55. Nilsson, S., Koehler, K.F., and Gustafsson, J.A. (2011). Development of subtype-selective oestrogen receptor-based therapeutics. Nature reviews. Drug discovery 10, 778-792.
56. Norris, J.D., Fan, D., Stallcup, M.R., and McDonnell, D.P. (1998). Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem 273, 6679-6688.
57. Nwachukwu, J.C., Li, W., Pineda-Torra, I., Huang, H.Y., Ruoff, R., Shapiro, E., Taneja, S.S., Logan, S.K., and Garabedian, M.J. (2007). Transcriptional regulation of the androgen receptor cofactor androgen receptor trapped clone-27. Mol Endocrinol 21, 2864-2876.
58. Nwachukwu, J.C., Southern, M.R., Kiefer, J.R., Afonine, P.V., Adams, P.D., Terwilliger, T.C., and Nettles, K.W. (2013). Improved crystallographic structures using extensive combinatorial refinement. Structure 21, 1923-1930.
59. Park, S.J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A.L., et al. (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433.
60. Patel, M.I., Gupta, A., and Dey, C.S. (2011). Potentiation of neuronal insulin signaling and glucose uptake by resveratrol: the involvement of AMPK. Pharmacological reports: PR 63, 1162-1168.
61. Perissi, V., Jepsen, K., Glass, C.K., and Rosenfeld, M.G. (2010). Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11, 109-123.
62. Peterson, T.J., Karmakar, S., Pace, M.C., Gao, T., and Smith, C.L. (2007). The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity. Molecular and cellular biology 27, 5933-5948.
63. Pfluger, P.T., Herranz, D., Velasco-Miguel, S., Serrano, M., and Tschop, M.H. (2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 105, 9793-9798.
64. Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J.S., et al. (2012). SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15, 675-690.
65. Rae, J.M., Johnson, M.D., Scheys, J.O., Cordero, K.E., Larios, J.M., and Lippman, M.E. (2005). GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast cancer research and treatment 92, 141-149.
66. Rajamohan, S.B., Pillai, V.B., Gupta, M., Sundaresan, N.R., Birukov, K.G., Samant, S., Hottiger, M.O., and Gupta, M.P. (2009). SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Molecular and cellular biology 29, 4116-4129.
67. Rogatsky, I., Luecke, H.F., Leitman, D.C., and Yamamoto, K.R. (2002). Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. Proc Natl Acad Sci U S A 99, 16701-16706.
68. Rothgiesser, K.M., Erener, S., Waibel, S., Luscher, B., and Hottiger, M.O. (2010). SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. Journal of cell science 123, 4251-4258.
69. Saijo, K., Collier, J.G., Li, A.C., Katzenellenbogen, J.A., and Glass, C.K. (2011). An ADIOL-ERbeta-CtBP Transrepression Pathway Negatively Regulates Microglia-Mediated Inflammation. Cell 145, 584-595.
70. Scheinman, R.I., Cogswell, P.C., Lofquist, A.K., and Baldwin, A.S., Jr. (1995). Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270, 283-286.
71. Shang, Y., and Brown, M. (2002). Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468.
72. Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. (2000). Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852.
73. Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero, R.A., and Shi, Y. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941-953.
74. Shi, Y., Sawada, J., Sui, G., Affar el, B., Whetstine, J.R., Lan, F., Ogawa, H., Luke, M.P., Nakatani, Y., and Shi, Y. (2003). Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422, 735-738.
75. Shi, Y.J., Matson, C., Lan, F., Iwase, S., Baba, T., and Shi, Y. (2005). Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 19, 857-864.
76. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., and Greene, G.L. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937.
77. Singh, U.P., Singh, N.P., Singh, B., Hofseth, L.J., Price, R.L., Nagarkatti, M., and Nagarkatti, P.S. (2010). Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. The Journal of pharmacology and experimental therapeutics 332, 829-839.
78. Srinivasan, S., Nwachukwu, J.C., Parent, A.A., Cavett, V., Nowak, J., Hughes, T.S., Kojetin, D.J., Katzenellenbogen, J.A., and Nettles, K.W. (2013). Ligand-binding dynamics rewire cellular signaling via estrogen receptor-alpha. Nat Chem Biol 9, 326-332.
79. Stenoien, D.L., Patel, K., Mancini, M.G., Dutertre, M., Smith, C.L., O'Malley, B.W., and Mancini, M.A. (2001). FRAP reveals that mobility of oestrogen receptor-alpha is ligand and proteasome-dependent. Nature cell biology 3, 15-23.
80. Sun, J., Nawaz, Z., and Slingerland, J.M. (2007). Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Mol Endocrinol 21, 2651-2662.
81. Tennen, R.I., Michishita-Kioi, E., and Chua, K.F. (2012). Finding a target for resveratrol. Cell 148, 387-389.
82. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M.J., Garcia-Almagro, F.J., Ruiz-Ros, J.A., Tomas-Barberan, F.A., Garcia-Conesa, M.T., and Espin, J.C. (2013). Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Annals of the New York Academy of Sciences 1290, 37-51.
83. Turner, R.T., Evans, G.L., Zhang, M., Maran, A., and Sibonga, J.D. (1999). Is resveratrol an estrogen agonist in growing rats? Endocrinology 140, 50-54.
84. Uhlenhaut, N.H., Barish, G.D., Yu, R.T., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hubner, N., and Evans, R.M. (2013). Insights into negative regulation by the glucocorticoid receptor from genome-wide profiling of inflammatory cistromes. Mol Cell 49, 158-171.
85. Wang, P., Min, J., Nwachukwu, J.C., Cavett, V., Carlson, K.E., Guo, P., Zhu, M., Zheng, Y., Dong, C., Katzenellenbogen, J.A., et al. (2012). Identification and Structure-Activity Relationships of a Novel Series of Estrogen Receptor Ligands Based on 7-Thiabicyclo[2.2.1]hept-2-ene-7-oxide. Journal of medicinal chemistry 55, 2324-2341.
86. Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., Liang, J., Sun, L., Yang, X., Shi, L., et al. (2009). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138, 660-672.
87. Warnmark, A., Treuter, E., Gustafsson, J.A., Hubbard, R.E., Brzozowski, A.M., and Pike, A.C. (2002). Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem 277, 21862-21868.
88. Webb, P., Nguyen, P., Shinsako, J., Anderson, C., Feng, W., Nguyen, M.P., Chen, D., Huang, S.M., Subramanian, S., McKinerney, E., et al. (1998). Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 12, 1605-1618.
89. Won Jeong, K., Chodankar, R., Purcell, D.J., Bittencourt, D., and Stallcup, M.R. (2012). Gene-specific patterns of coregulator requirements by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol 26, 955-966.
90. Wong, C.W., Komm, B., and Cheskis, B.J. (2001). Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. Biochemistry 40, 6756-6765.
91. Wu, Z., Li, Y., Li, X., Ti, D., Zhao, Y., Si, Y., Mei, Q., Zhao, P., Fu, X., and Han, W. (2011). LRP16 integrates into NF-kappaB transcriptional complex and is required for its functional activation. PLoS One 6, e18157.
92. Xu, J., and Li, Q. (2003). Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17, 1681-1692.
93. York, B., and O'Malley, B.W. (2010). Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem 285, 38743-38750.
94. Yu, C., York, B., Wang, S., Feng, Q., Xu, J., and O'Malley, B.W. (2007). An essential function of the SRC-3 coactivator in suppression of cytokine mRNA translation and inflammatory response. Mol Cell 25, 765-778.
95. Yu, E.J., Kim, S.H., Heo, K., Ou, C.Y., Stallcup, M.R., and Kim, J.H. (2011a). Reciprocal roles of DBC1 and SIRT1 in regulating estrogen receptor alpha activity and co-activator synergy. Nucleic Acids Res 39, 6932-6943.
96. Yu, H.P., Hsu, J.C., Hwang, T.L., Yen, C.H., and Lau, Y.T. (2008). Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock 30, 324-328.
97. Yu, H.P., Hwang, T.L., Hsieh, P.W., and Lau, Y.T. (2011b). Role of estrogen receptor-dependent upregulation of P38 MAPK/heme oxygenase 1 in resveratrol-mediated attenuation of intestinal injury after trauma-hemorrhage. Shock 35, 517-523.
98. Yu, H.P., Hwang, T.L., Hwang, T.L., Yen, C.H., and Lau, Y.T. (2010). Resveratrol prevents endothelial dysfunction and aortic superoxide production after trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway. Critical care medicine 38, 1147-1154.
99. Zhang, T., Berrocal, J.G., Frizzell, K.M., Gamble, M.J., DuMond, M.E., Krishnakumar, R., Yang, T., Sauve, A.A., and Kraus, W.L. (2009). Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem 284, 20408-20417.
100. Zhang, T., Berrocal, J.G., Yao, J., Dumond, M.E., Krishnakumar, R., Ruhl, D.D., Ryu, K.W., Gamble, M.J., and Kraus, W.L. (2012). Regulation of Poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD+ synthase. J Biol Chem.